Adjuvance Technologies Announces Issuance of U.S. Patent Covering Semi-Synthetic Saponin Adjuvants
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,906,926. The patent is directed to triterpene saponin analogues, specifically Adjuvance’s next generation saponin adjuvant TQL-1055, which exhibits improved adjuvant activity and reduced toxicity as compared to QS-21.
U.S. Patent No. 10,906,926 protects the TQL-1055 composition of matter, pharmaceutical compositions incorporating TQL-1055, methods of using TQL-1055 for immunization against infections, and methods for obtaining TQL-1055. The patent includes 21 claims and follows issuance of similar patents in certain other countries around the world.
The patent has been assigned to Adjuvance and Memorial Sloan Kettering Cancer Center (New York, USA), where advanced synthetic saponin technology was first developed. Adjuvance exclusively licensed MSK’s foundational technology in 2011 and has since continued to innovate. Adjuvance seeks to apply TQL-1055 in improved vaccine compositions, including an improved shingles vaccine expected to enter clinical development during 2022. Adjuvance will continue to develop its vaccine adjuvant technology by creating, developing, and manufacturing a family of next-generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships.
MSK Disclosure: Memorial Sloan Kettering Cancer Center (MSK) has intellectual property rights and associated financial interests related to Adjuvance Technologies by virtue of licensing agreements between MSK and Adjuvance Technologies.
About TQL-1055: TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant, which is used in the currently available shingles vaccine. Saponin adjuvants are potent immune stimulators and important components of licensed, currently marketed, and clinically-advanced infectious disease vaccines. The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. TQL-1055 is designed to have improved tolerability and to provide the same strong immune response as QS-21 and has shown favorable tolerability in a Phase 1 clinical trial. Adjuvance is designing new combination adjuvants, with TQL-1055 as the foundation, to produce different types of immune responses.
About Shingles: Shingles (also known as herpes zoster) is a painful rash that develops, often on the face or torso, and has the potential complication of pain that can last for months or even years. Vaccination against shingles is recommended in the United States and many countries for older adults and people with weak immune systems, resulting in a market value of over $2.0 billion in 2020. Available shingles vaccines contain the saponin adjuvant QS-21 and the toll-like receptor (TLR) 4 agonist adjuvant monophosphoryl lipid A (MPL), known together as the AS01 adjuvant. The adjuvanted shingles vaccine is highly effective, but can cause short-term adverse events more intense than other vaccines. About 1 out of 6 people who got the available shingles vaccine experienced side effects that prevented them from doing regular activities. Symptoms went away on their own in about 2 to 3 days.
About Adjuvance Technologies: Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our lead vaccine candidate against shingles aims to provide a better patient experience including improved tolerability for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institutes of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Senior Account Executive
Chief Executive Officer
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chemours Details Progress in its Fifth Corporate Responsibility Commitment Report9.8.2022 13:30:00 CEST | Press release
The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, today announced the fifth edition of its annual Corporate Responsibility Commitment (CRC) Report, inclusive of updates on the company’s ESG targets. The report showcases the company’s collective determination and commitment to making chemistry as responsible as it is essential while delivering tremendous progress to meet its goals. Select report highlights from the company’s 2021 operations include: Made substantial progress toward achieving the company's goal to reduce air and water process emissions of fluorinated organic compounds by 99% or more by 2030, reaching a 40% global reduction since 2018. Generated 47.2% of total 2021 revenue from offerings that make a specific contribution to the United Nation’s Sustainable Development Goals (UN SDGs). Achieved the company’s sustainable supply c
The Anomali Platform Advances Intelligence-Driven Detection and Response Capabilities and Prevents Business Disruptions While Optimizing Security Expense9.8.2022 13:30:00 CEST | Press release
Anomali, the leader in intelligence-driven cybersecurity solutions, announced the general availability today of its quarterly platform update to meet the expanding needs of its customers and partners. This release introduces new capabilities to enhance Anomali’s threat intelligence and extended detection and response (XDR) use cases that enable enterprise organizations to stay one step ahead of adversaries and prevent business disruptions while optimizing security expenses. “Anomali’s August release offers new capabilities and enhancements for security operations teams struggling to identify not only who’s targeting them, but how and why they are being targeted,” said Mark Alba, Chief Product Officer at Anomali. Key highlights of this release include: Creating Extended Visibility with Anomali Attack Pattern Detection and MITRE ATT&CK®: In 2021, Anomali joined MITRE Engenuity’s Center for Threat-Informed Defense to collaborate on the Attack Flow Project to better understand adversary be
Corona Spearheads Eco-Tourism with Corona Island, the World’s First Blue Verified, Single-Use Plastic-Free Island9.8.2022 13:11:00 CEST | Press release
Today, global beer brand Corona announces the grand opening of Corona Island, a tropical sustainable destination for eco-tourism off the coast of Colombia. A first-of-its-kind island paradise, Corona Island is free of single-use plastic, encouraging guests to reconnect with the natural world through immersive hospitality experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005308/en/ Corona Island (Photo: Business Wire) As a beer made with natural ingredients that was born at the beach and the first global beverage brand with a net-zero plastic footprint*, Corona partnered with international nonprofit Oceanic Global to create the first Blue Verified island. Corona Island has achieved Oceanic Global’s three-star plastic-free Blue Seal for eliminating single-use plastic and adopting sustainable operating best practices at scale. From construction to energy production, food sourcing and guest experiences on-site, s
Q4 Inc. Announces Appointment of Chief Financial Officer9.8.2022 13:00:00 CEST | Press release
Q4 Inc. (TSX: QFOR), a leading capital markets communications platform, today announced the appointment of Donna de Winter as chief financial officer (CFO) effective August 8, 2022. Ms. de Winter has been serving as interim CFO since May 31, 2022. “On behalf of the Q4 Board and the entire Q4 team, we are thrilled to announce that Donna has assumed the role of CFO, after serving in an interim capacity for the last few months,” said Darrell Heaps, CEO. “We are incredibly fortunate to benefit from Donna’s breadth of industry expertise across finance, strategy and operations. Donna has added tremendous value to Q4 over the last few years as Chief Operating Officer, and her lens of operational knowledge along with her strong background as a financial leader of both private and publicly traded companies brings a powerful combination and perspective to the CFO role. We look forward to benefiting from Donna’s deep bench of experience as we pursue our strategic vision and path to profitability.
Aria Systems to Showcase TM Forum Catalyst Solution at Digital Transformation World9.8.2022 13:00:00 CEST | Press release
Aria Systems, the leader in helping enterprises grow subscription and usage-based revenue, today announced the company will be at Digital Transformation World (DTW) in September to present the findings and solution resulting from its involvement in one of TM Forum’s most championed catalyst programs. Aria and its partners have been exploring how an event-driven architecture can enable service providers to build more scalable and flexible IT architecture with lower integration costs, and faster time to market. Catalysts are proof-of-concept projects developed collaboratively by members to solve problems presented by leading global communications service providers (CSPs) and define and propose new industry standards. Together with its partners and CSP champions, Aria will demonstrate how the Open Digital Framework (ODF) can be enhanced for organizations that have adopted a modern event-driven architecture. “As CSPs transform their BSS solution with best-of-breed capabilities to support n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom